STOCK TITAN
  1. Home
  2. Sec-filings
  3. EIKN
  4. [8-K] Eikon Therapeutics, Inc. Reports Material Event

Eikon Therapeutics (EIKN) cuts quarterly loss and boosts cash to $531M

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. reported second quarter 2026 results and extensive clinical progress across its oncology pipeline. The company ended the quarter with $531.2 million in cash, cash equivalents and marketable securities and expects this balance to fund operations into the second half of 2027. Net loss attributable to common stockholders was $88.4 million, compared with $105.2 million a year earlier.

Research and development expenses for the quarter were $75.5 million, up from $69.2 million, reflecting increased clinical trial activity. General and administrative expenses declined sharply to $17.9 million from $40.5 million, primarily due to prior-year impairments that did not recur. Total stockholders’ equity improved to $466.5 million at June 30, 2026, from a deficit of $(879.0) million at December 31, 2025.

Clinically, Eikon highlighted seven accepted abstracts for ESMO 2026 covering all four current clinical candidates, encouraging combination data for EIK1001 in NSCLC and melanoma, and advancing Phase 1/2 programs for PARP1 inhibitors EIK1003 and EIK1004, WRN helicase inhibitor EIK1005, and planned IND submission for AR antagonist EIK1006 by year-end 2026.

Positive

  • Net loss narrowed to $88.4 million from $105.2 million year over year, indicating reduced operating deficit.
  • G&A expenses fell 56% to $17.9 million from $40.5 million, helped by the absence of prior-year impairment charges.
  • Cash, cash equivalents and marketable securities reached $531.2 million, with runway expected into the second half of 2027.
  • Balance sheet strengthened as total stockholders’ equity improved to $466.5 million from a $(879.0) million deficit.
  • Pipeline advanced with multiple Phase 2/3 registrational trials and seven oncology abstracts accepted for ESMO 2026.

Negative

  • Substantial net loss of $88.4 million in Q2 2026 underscores the company’s ongoing cash burn.
  • R&D expenses increased to $75.5 million from $69.2 million, reflecting higher spending on clinical trials.

Filing Explained

An independent director joined Eikon’s board and Compensation Committee; the accompanying results material was furnished, not filed.

On August 13, 2026, Eikon Therapeutics appointed Fatima D. Francisco as an independent director and to the Board’s Compensation Committee, changing the company’s board and committee membership.

The financial and clinical update in Item 2.02, including Exhibit 99.1, was furnished rather than filed and is not subject to specified Exchange Act and Securities Act liability provisions or incorporated by reference into other filings except as expressly stated.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Cash, cash equivalents and marketable securities $531.2 million As of June 30, 2026; expected to fund operations into the second half of 2027
Net loss attributable to common stockholders $88.4 million Three months ended June 30, 2026; compared with $105.2 million in prior-year quarter
Research and development expenses $75.5 million Three months ended June 30, 2026; up from $69.2 million, a 9% increase
General and administrative expenses $17.9 million Three months ended June 30, 2026; down from $40.5 million, a 56% decrease
Total stockholders’ equity (deficit) $466.5 million June 30, 2026; improved from $(879.0) million at December 31, 2025
Total operating expenses $93.4 million Three months ended June 30, 2026; versus $109.6 million in prior-year quarter
Interest income, net $5.0 million Three months ended June 30, 2026; compared with $4.4 million in prior-year period
registrational trial medical
"TeLuRide-006 Phase 2/3 registrational trial evaluating EIK1001 in combination"
A registrational trial is the large, definitive clinical study designed to provide the evidence regulators need to decide whether a new drug or medical product can be approved for sale. Think of it as the final exam for a treatment: passing it can unlock widespread market access and potential revenues, while failing it can sharply reduce a product’s commercial prospects and raise investment risk.
PARP1 inhibitors medical
"EIK1003 and EIK1004 are highly selective PARP1 inhibitors designed to inhibit"
PARP1 inhibitors are a class of medicines that block a cell enzyme (PARP1) responsible for repairing damaged DNA, causing cancer cells that already have weak repair systems to die. They matter to investors because they represent a targeted cancer treatment with potential for strong sales, patent value, and regulatory milestones; success often hinges on clinical trial results, approval decisions, and companion tests that identify patients likely to benefit.
microsatellite instability-high (MSI-high) medical
"EIK1005 has the potential to be an effective anti-tumor agent for microsatellite instability-high (MSI-high) tumors"
single molecule tracking system technical
"including its proprietary single molecule tracking system, to develop internally derived novel therapies"
synthetic lethality medical
"by producing synthetic lethality in MSI-high cells that depend upon the WRN helicase"
Synthetic lethality occurs when two separate weaknesses in a cell—each harmless alone—combine to cause the cell to die; targeting the partner weakness lets a drug kill diseased cells while sparing healthy ones. Think of it like removing the second support of a wobbly chair: a targeted nudge collapses only the defective ones. For investors, therapies based on this idea can offer more precise drugs, clearer patient selection tests, and potentially faster, less risky development paths.
investigational new drug application (IND) regulatory
"Eikon expects to submit an investigational new drug application (IND) for EIK1006"
An investigational new drug application (IND) is a formal request made to regulatory authorities to begin testing a new medicine in humans. It is a crucial step in the drug development process, allowing companies to conduct clinical trials to determine if the drug is safe and effective. For investors, an IND signals progress in the drug's development, which can influence a company's potential growth and valuation.
Net loss attributable to common stockholders $88.4 million Compared with $105.2 million net loss in the prior-year quarter
Research and development expenses $75.5 million Increased from $69.2 million, a 9% rise year over year
General and administrative expenses $17.9 million Decreased from $40.5 million, a 56% reduction year over year
Cash, cash equivalents and marketable securities $531.2 million Up from $335.975 million at December 31, 2025
Guidance

The company expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2027 and outlined multiple upcoming data presentations at ESMO 2026 and an anticipated IND submission for EIK1006 by the end of 2026.

FAQ

What were Eikon Therapeutics (EIKN) key financial results for Q2 2026?
For Q2 2026, Eikon reported a net loss of $88.4 million, compared with $105.2 million a year earlier. R&D expenses were $75.5 million and G&A expenses were $17.9 million, reflecting higher development spending but lower overhead.

What is Eikon Therapeutics (EIKN) cash position and runway after Q2 2026?
As of June 30, 2026, Eikon held $531.2 million in cash, cash equivalents, and marketable securities. The company expects this to fund operations into the second half of 2027, supporting multiple ongoing and planned clinical trials.

How did Eikon Therapeutics (EIKN) operating expenses change year over year?
In Q2 2026, R&D expenses rose to $75.5 million from $69.2 million, while G&A expenses dropped to $17.9 million from $40.5 million. The G&A decline was primarily driven by non-recurring impairment charges recorded in the prior-year period.

What clinical milestones did Eikon Therapeutics (EIKN) highlight for EIK1001?
Eikon reported a first interim analysis of the TeLuRide-006 Phase 2/3 trial in advanced melanoma, continued TeLuRide-005 data in NSCLC, and first-patient dosing in TeLuRide-008, a Phase 2/3 registrational NSCLC study combining EIK1001 with pembrolizumab and chemotherapy.

What are the upcoming data presentations for Eikon Therapeutics (EIKN) at ESMO 2026?
Eikon will present seven abstracts at ESMO 2026, including full combination data for EIK1001 in NSCLC, updated EIK1003 monotherapy and combination data, initial EIK1004 and EIK1005 Phase 1/2 data, and multiple cohort results across advanced solid tumors.

How has Eikon Therapeutics (EIKN) balance sheet changed in 2026?
By June 30, 2026, total assets were $779.6 million and total stockholders’ equity was $466.5 million, compared with a stockholders’ deficit of $(879.0) million at December 31, 2025, reflecting a significantly strengthened capital structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000186112300018611232026-08-132026-08-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

 

 

EIKON THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-43085

84-2807586

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

230 Harriet Tubman Way

 

Millbrae, California

 

94030

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (341) 777-0566

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

EIKN

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

Description

99.1

 

Press Release dated August 13, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EIKON THERAPEUTICS, INC.

 

 

 

 

Date:

August 13, 2026

By:

/s/ Alfred Bowie, Ph.D.

 

 

 

Alfred Bowie, Ph.D.
Chief Financial Officer

 

Exhibit 99.1

Eikon Therapeutics Reports Second Quarter 2026 Financial Results

and Provides Clinical Updates

 

•
Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005

 

•
Presented data at the American Society for Clinical Oncology (ASCO) 2026 Annual Meeting demonstrating encouraging activity of EIK1001 combined with pembrolizumab and histology-appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC in the TeLuRide-005 Phase 2 trial, and preliminary evidence that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel in second-line treatment of breast and ovarian cancers

 

•
Progressed the TeLuRide-006 Phase 2/3 registrational trial of EIK1001 through a first interim analysis, including dose-optimization in first-line advanced melanoma

 

•
Appointed Ma. Fatima “Fama” Francisco to the Board of Directors, adding decades of global commercial experience

 

•
Ended second quarter of 2026 with $531.2 million in cash, cash equivalents and marketable securities

 

MILLBRAE, Calif., August 13, 2026 -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported second quarter 2026 financial results and provided updates on its programs.

 

“The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for presentation at the upcoming ESMO conference in October in Madrid,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics. “These new results expand what we reported at the ASCO conference in June and advance our ability to address important unmet needs in cancer therapy. Moreover, our clinical progress reinforces the conclusion that Eikon’s unique research platform can reproducibly elucidate novel approaches towards the treatment of grievous illness.”

 

Clinical Development Highlights

 

EIK1001

 

EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to stimulate both innate and adaptive immune responses to malignancy. Eikon believes that its data

DRAFT

 

generated to date show that intravenous administration of EIK1001 has been generally well-tolerated, activates readily measured systemic immune responses, and can be combined with current standard-of-care for the treatment of malignant disease.

 

•
Eikon will present comprehensive updated data from TeLuRide-005 (NCT06246110), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with non–small cell lung cancer (NSCLC), on Monday, October 26 at the ESMO Congress 2026 in Madrid, Spain.

 

•
On August 11, 2026, Eikon reported that a first interim analysis of TeLuRide-006 (NCT06697301), an ongoing global Phase 2/3 registrational trial evaluating EIK1001 in combination with pembrolizumab in the first-line treatment of advanced melanoma, was completed by an independent Data Monitoring Committee (DMC). The DMC selected, per protocol, a single dosing regimen for expansion of the trial, and recommended that the study continue as planned.

 

•
On July 27, 2026, Eikon announced dosing of the first patient in TeLuRide-008 (NCT07365319), a Phase 2/3 registrational trial evaluating EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naive patients with stage 4 NSCLC.

 

•
On May 30, 2026, Eikon presented updated data at the 2026 ASCO Annual Meeting from TeLuRide-005 (NCT06246110), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with non-small cell lung cancer (NSCLC). Among other results, the presentation showed:

 

 

o
When combined with standard-of-care therapy, EIK1001 was observed to be associated with meaningful and consistent clinical activity across PD-(L)1 tumor proportion score subgroups
o
EIK1001 was observed to be generally well tolerated, permitting administration in the outpatient setting
o
Durable anti-tumor activity with median response duration of greater than 11 months for the non-squamous cohort was observed

 

A more complete characterization of these durable responses will be presented at the ESMO Congress 2026 in October.

 

 

EIK1003 & EIK1004

DRAFT

 

 

EIK1003 and EIK1004 are highly selective PARP1 inhibitors designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1004 was specifically engineered to penetrate the central nervous system (CNS), potentially expanding the utility of selective PARP1 inhibition to tumors involving the brain and CNS. Eikon believes the selectivity of EIK1003 and EIK1004 may enable the development of near full-dose combination regimens with chemotherapy, antibody-drug conjugates, or radionuclides, in earlier lines of therapy than currently possible with non-selective PARP inhibitors, and will potentially allow for more sustained therapeutic dosing during maintenance treatment.

 

•
Eikon will present clinical data from its ongoing Phase 1/2 trial of EIK1003 on Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain. Various trial components evaluate the safety and efficacy of EIK1003 as monotherapy or in combination with anti-cancer agents in participants with advanced solid tumors (NCT06253130). The presentations will include updated data from Cohorts 1A and 1C, as well as initial data from Cohort 1B, which is specifically evaluating the safety and preliminary efficacy of EIK1003 in combination with abiraterone and prednisone for the treatment of patients with advanced prostate cancer.

 

•
Eikon is also currently enrolling an additional Cohort 1D, evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapeutic regimens in patients with ovarian cancer. Site selection for Cohort 1D is completed and enrollment is ongoing.

 

•
Eikon is currently evaluating two dose levels of EIK1003 monotherapy, 20 mg and 60 mg, to determine the optimal Phase 2 dose for EIK1003. Approximately 30 PARPi-naïve, HER2-negative breast cancer patients are expected to be enrolled at each dose level. Enrollment for the Part 2 dose optimization portion of the Phase 1/2 trial is ongoing.

 

•
On Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain, Eikon will also present, for the first time, data from an ongoing Phase 1/2 trial evaluating the safety and efficacy of EIK1004, a selective PARP1 inhibitor designed to penetrate the CNS, for the treatment of patients with ovarian, breast, prostate, and pancreatic cancers (NCT06907043). Eikon believes that these results, together with data from its studies of EIK1003, will provide mutually reinforcing insights into the behavior of highly-selective PARP1 inhibitors.

 

•
On May 30, 2026, Eikon presented data at the 2026 ASCO Annual Meeting from its ongoing Phase 1/2 trial evaluating the safety and efficacy of EIK1003 as monotherapy or in combination with anti-cancer agents in participants with advanced solid tumors (NCT06253130), including:

DRAFT

 

o
Updated clinical safety, tolerability and preliminary efficacy data from Cohort 1A, evaluating EIK1003 as a monotherapy for the treatment of patients with ovarian, breast, prostate, and pancreatic cancers

 

o
Initial clinical safety, tolerability and preliminary efficacy data from Cohort 1C, evaluating EIK1003 in combination with paclitaxel for the treatment of patients with platinum-resistant ovarian, or breast cancer patients who are either HER2-negative, ER-positive, and hormonal therapy-experienced, or ER-negative and chemotherapy-experienced.

 

EIK1005

 

EIK1005 is a novel molecular entity, designed to inhibit the Werner (“WRN”) helicase, that emerged from original research conducted in Eikon’s laboratories. Eikon believes that EIK1005 has the potential to be an effective anti-tumor agent for microsatellite instability-high (MSI-high) tumors, by producing synthetic lethality in MSI-high cells that depend upon the WRN helicase salvage pathway to maintain genome integrity.

 

•
Eikon is currently evaluating EIK1005 in a Phase 1/2 trial as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors (NCT07262619). The first patient in this Phase 1/2 dose-escalation trial was dosed in January 2026.

 

•
Preliminary safety, tolerability and pharmacokinetic data for EIK1005 will be presented on Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain.

 

EIK1006

 

EIK1006 is another internally-derived clinical candidate and is being investigated as a potential next-generation androgen receptor (“AR”) antagonist with activity against multiple clinically important genetic variants of AR that emerge during treatment with conventional AR blockers. Preclinically, Eikon scientists have shown that EIK1006 binds to the ligand binding domain of AR and blocks its nuclear translocation, thereby inhibiting AR transcriptional activity and downstream signaling.

 

•
Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026.

 

Key Upcoming Milestones

 

•
EIK1001: Presenting full combination data from the TeLuRide-005 trial in NSCLC on Monday, October 26 at ESMO.
•
EIK1003: Presenting updated Phase 1/2 monotherapy and combination data in patients with advanced solid tumors across Cohorts 1A, 1B and 1C on Friday, October 23 at the ESMO Congress 2026.

DRAFT

 

•
EIK1004: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at ESMO.
•
EIK1005: Presenting initial Phase 1/2 data in patients with advanced solid tumors on Friday, October 23 at the ESMO Congress 2026.
•
EIK1006: Expects to submit an IND by the end of 2026.

 

Second Quarter 2026 Corporate Highlights

 

Appointment of Ma. Fatima D. Francisco to Board of Directors

 

Eikon appointed Ma. Fatima (“Fama”) D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee.

 

Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co.

 

Second Quarter 2026 Financial Results

 

Cash Position: As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.

Research and Development (“R&D”) Expenses: R&D expenses were $75.5 million for the three months ended June 30, 2026, compared to $69.2 million for the three months ended June 30, 2025, an increase of $6.3 million, or 9%. Direct research and development expenses increased by $12.8 million as we advanced our clinical trial activity, and compensation costs increased by $1.7 million. These increases were partially offset by restructuring expenses and milestone payments in the prior year period and by lower occupancy costs.

General and Administrative (“G&A”) Expenses: G&A expenses were $17.9 million for the three months ended June 30, 2026, compared to $40.5 million for the three months ended June 30, 2025, a decrease of $22.5 million, or 56%. The decrease was primarily due to the impairment in the year-ago period of $10.7 million of property and equipment and $10.3 million of operating lease right-of-use assets relating to properties in Hayward, California that Eikon vacated in April 2025 when the Company moved into its current corporate headquarters in Millbrae, California.

Net Loss: Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026, compared to $105.2 million for the prior-year period.

“Our strong balance sheet enables us to continue to support an increasingly mature pipeline, including ongoing registrational studies of EIK1001 in both advanced melanoma and non-small cell lung cancer,” said Freddie Bowie, Ph.D., Chief Financial

DRAFT

 

Officer. “Additional development programs to be reviewed at ESMO demonstrate our ability to execute global clinical trials across multiple indications. We remain focused on deploying capital toward opportunities that we believe have the potential to significantly enhance shareholder value over the next few years.”

 

About Eikon Therapeutics

Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates that could eventually become lifesaving medicines. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

 

Forward-Looking/Safe Harbor Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon’s anticipated presentations at the ESMO Congress 2026 and the anticipated cash runway into the second half of 2027; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

 

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: Eikon’s limited operating history; its significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; its need for substantial additional funding; the early stage of development of many of its product candidates and the possibility that its product candidates may fail in development; its dependence on the success of its current product candidates; its ability to leverage its technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report

DRAFT

 

on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

 

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

 

Contacts:

 

Investors

Alfred “Freddie” Bowie, Ph.D., CFO

ir@eikontx.com

 

Media

Colin Sanford

colin@bioscribe.com

 

 

 

DRAFT

 

Eikon Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)

 

 

(in thousands, except share and per share amounts)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2026

 

2025

 

2026

 

2025

Operating expenses:

 

 

 

 

 

 

 

Research and development

 $ 75,460

 

 $ 69,189

 

 $ 145,507

 

 $ 125,776

General and administrative

         17,934

 

       40,454

 

         35,224

 

       55,250

Total operating expenses

         93,394

 

     109,643

 

       180,731

 

     181,026

Loss from operations

       (93,394)

 

   (109,643)

 

     (180,731)

 

   (181,026)

Interest income (expense), net

           5,037

 

         4,434

 

           9,417

 

         7,594

Other income (expense), net

              (52)

 

              (2)

 

              (53)

 

            (22)

Net loss and comprehensive loss

       (88,409)

 

   (105,211)

 

     (171,367)

 

   (173,454)

Impact of preferred stock extinguishments and modifications

                —

 

              —

 

                —

 

       (9,396)

Net loss attributable to common stockholders

 $ (88,409)

 

 $(105,211)

 

 $ (171,367)

 

 $(182,850)

Net loss per share attributable to common stockholders, basic and
   diluted

 $ (1.63)

 

 $ (36.94)

 

 $ (3.90)

 

 $ (65.08)

Weighted-average shares of common stock outstanding used in
   computing net loss per share attributable to common
   stockholders, basic and diluted

  54,143,162

 

  2,848,529

 

  43,978,373

 

  2,809,691

 

Eikon Therapeutics, Inc.

Condensed Balance Sheet Data

(in thousands)

(Unaudited)

 

(in thousands)

 

June 30,
2026

 

December 31,
2025

Cash, cash equivalents and marketable securities

 $ 531,178

 

 $ 335,975

Total assets

                     779,570

 

                     594,734

Total liabilities

                     313,070

 

                     312,298

Total stockholders’ equity (deficit)

                     466,500

 

                   (879,034)

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents